This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin).
We have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents.
This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use.
PT is a promising treatment option for prostate cancer patients. Studies have already demonstrated extremely low rates of grade > 3 GU and GI toxicities and extremely high disease control, presumably related to improved radiation dose distributions over what can be achieved with IMRT.
A threshold has clearly been crossed in the management of advanced prostate cancer; however, the impact on survival has been relatively modest, and efforts at personalized therapy have lagged behind those for other solid tumors.
This article presents a review of the literature on screening for prostate cancer with PSA testing; we include a detailed discussion of potential explanations for the contradictory results of the two largest randomized trials as well as reflections on the future of prostate cancer screening.
Although the majority of patients with advanced prostate cancer have an initial response to androgen deprivation, essentially all patients eventually progress to a castration-resistant state, manifested by rising levels of prostate-specific antigen (PSA),
In recent years new therapies have begun to emerge to treat this devastating form of prostate cancer. This review examines the mechanisms behind these therapeutics and the key trials seeking to validate their clinical use.
The increase in the prevalence of obesity, diabetes, dyslipidemia, and hypertension has resulted in a marked increase in the prevalence of metabolic syndrome.
Core biopsy of prostate from an elderly male. Your diagnosis is:
- A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
- Head and Neck Tumors
- A 45-Year-Old Woman Presents With Severe Back Pain; Examination Reveals Nephrolithiasis
- A 58-Year-Old Man Presents With Abdominal Pain and Jaundice
- Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies
|
JOB LISTINGS
Post a job
Powered by SearchMedica Jobs
CONNECT WITH US
|
|
||||||||||||||
CancerNetwork |
ConsultantLive |
Diagnostic Imaging |
Musculoskeletal Network |
OBGYN.net |
PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2012 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy